AOD-9604 research guide

AOD-9604 in Diseröd — Fat Loss Peptide Research Guide

AOD-9604 research guide for Diseröd. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Diseröd Guide to AOD-9604 Research

Unlike everyday supplements stocked in every health store, AOD-9604 is distributed via a specialist research supply market that Diseröd residents access almost entirely online. This matters because AOD-9604 quality differs enormously across the market — from analytically confirmed high-purity product to mislabeled or underdosed compounds — and the vendor determines everything about the product. Separating properly characterised AOD-9604 from the rest of the market requires three things: an HPLC chromatogram documenting ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Diseröd researchers need to know about finding, evaluating, and storing AOD-9604 for scientific research use.

What Studies Say About AOD-9604

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Diseröd comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

Where to Buy AOD-9604 — A Researcher's Guide

Before assessing any particular supplier, establish a quality benchmark — so you can tell whether a COA is complete and credible. The HPLC analytical chromatogram is the most important document in the COA: it should show a large primary peak representing AOD-9604, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. For Diseröd researchers evaluating new suppliers: a test quantity before committing to research volumes before scaling up your order is what experienced peptide researchers consistently do. Bacteriostatic water is the correct reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to 4 weeks when kept refrigerated.

Order AOD-9604 — ships to Diseröd
COA-verified · International tracking · Research grade
Order Now →

AOD-9604: Storage, Reconstitution & Safety

AOD-9604 is sold for research purposes only and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is for educational purposes only. Lyophilised AOD-9604 should be placed in the freezer at −20°C straight away; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. Bacterial endotoxin contamination is the most serious safety risk unique to this class of compound — verify endotoxin testing is included in the batch-specific COA before any injectable research application. The research literature on AOD-9604 should be read critically before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and conclusions do not uniformly extrapolate.

Frequently Asked Questions

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →